{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:35:28Z","timestamp":1790422528905,"version":"4.1.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"12","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2021,8,6]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Glycogen synthase kinase 3 (GSK-3) is a serine\/threonine kinase enzyme\nthat controls neuronal functions such as neurite outgrowth, synapse formation, neurotransmission,\nand neurogenesis. The enzyme has two subunits as GSK-3\u03b1 and GSK-3\u03b2. 4ACC, 1Q3D, 3AFG,\n1UV5, and 1Q5K are the important GSK-3 receptors isolated from Homo sapiens and Mus musculus.\nThis enzyme mainly phosphorylates Tau protein with the increased amount in neuronal fibres\ntogether with beta-amyloid plaques that cause neuronal diseases like Alzheimer's, Parkinson\u2019s and\nmany more.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>We investigated the developments of various synthetic GSK-3 inhibitors responsible for\nthe prevention and treatment of neurological disorders, like Alzheimer's disease, bipolar disorders,\nacting as antidepressants, neuroprotective, etc.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results and Conclusion:<\/jats:title>\n<jats:p> It has been observed that structures of the GSK-3 inhibitors are comprised\nof benzopyridine, benzothiazole, pyrazole, pyrazine, dioxolo-benzoxazine, oxadiazole, and\nbenzimidazole in the skeletal with cyclopropyl amide, phenyl carbamothioate, 3-[(propan-\n2-yl)oxy]propan-1-amine in the side chain. The molecules were evaluated against the effectivity\nof GSK-3, human adenosine kinase, cyclin-dependent kinase, and phosphodiesterase-4 along\nwith tail suspension test forced swim test, percent neuronal survival and other cognitive behaviours.\nThe observations confirmed the remarkable effects of the synthesized molecules to conquer\nAlzheimer, Parkinson\u2019s depression, psychosis and other forms of neurological disorders.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389450122666210120143953","type":"journal-article","created":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T09:45:39Z","timestamp":1611654339000},"page":"1437-1462","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Recent Advances in the Discovery of GSK-3 Inhibitors from Synthetic Origin in the Treatment of Neurological Disorders"],"prefix":"10.2174","volume":"22","author":[{"given":"Supriyo","family":"Saha","sequence":"first","affiliation":[{"name":"School of Pharmaceutical Sciences & Technology, Sardar Bhagwan Singh University, Dehradun-248161, Uttarakhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9623-1617","authenticated-orcid":true,"given":"Dilipkumar","family":"Pal","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, C.G., 495 009, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish B.","family":"Nimse","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Hallym University, Kangwon-do, Chuncheon, 200 702, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/190504","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/190504\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/190504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T19:46:24Z","timestamp":1628538384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/190504\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,6]]},"references-count":0,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,8,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450122666210120143953","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-08-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}